Top

Published in:

01-09-2017 | Topic Review

The evolving role for re-irradiation in the management of recurrent grade 4 glioma

Authors: Steven P. Howard, Andra Krauze, Mike D. Chan, Christina Tsien, Wolfgang A. Tomé

Published in: Journal of Neuro-Oncology | Issue 3/2017

Abstract

Although significant gains have been realized in the management of grade 4 glioma, the majority of these patients will ultimately suffer local recurrence within the prior field of treatment. Clearly, novel local treatment strategies are required to improve patient outcomes. Concerns of toxicity have limited enthusiasm for the utilization of re-irradiation as a treatment option. However, using modern imaging technology and precision radiotherapy delivery techniques re-irradiation has proven a feasible option achieving both a palliative benefit and prolongation of survival with low toxicity rates. The evolution of re-irradiation as a treatment modality for recurrent grade 4 glioma is reviewed. In addition, potential targeted radiosensitizers to be used in conjunction with re-irradiation are also discussed.

Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, Gutin PH, Larson DA (1996) Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36(2):433–441CrossRefPubMed

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

Hegi ME, Stupp R (2015) Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter–still a dilemma? Neuro Oncol 17(11):1425–1427. doi:10.1093/neuonc/nov198 CrossRefPubMedPubMedCentral

Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM (2015) Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. J Neurooncol 122(3):559–566. doi:10.1007/s11060-015-1745-x CrossRefPubMed

Wick W, Fricke H, Junge K, Kobyakov G, Martens T, Heese O, Wiestler B, Schliesser MG, von Deimling A, Pichler J, Vetlova E, Harting I, Debus J, Hartmann C, Kunz C, Platten M, Bendszus M, Combs SE (2014) A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma. Clin Cancer Res 20(24):6304–6313. doi:10.1158/1078-0432.CCR-14-0951-T CrossRefPubMed

Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougere C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J Neurooncol 117(2):337–345. doi:10.1007/s11060-014-1394-5 CrossRefPubMed

Scholtyssek F, Zwiener I, Schlamann A, Seidel C, Meixensberger J, Bauer M, Hoffmann KT, Combs SE, von Bueren AO, Kortmann RD, Muller K (2013) Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort. Radiat Oncol 8:161. doi:10.1186/1748-717X-8-161 CrossRefPubMedPubMedCentral

Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V, Enrici RM (2013) Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. J Neurooncol 111(2):187–194. doi:10.1007/s11060-012-0999-9 CrossRefPubMed

Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, Zhang Z, Lassman AB, Abrey LE, Gutin PH (2013) Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 85(3):636–642. doi:10.1016/j.ijrobp.2012.05.031 CrossRefPubMed

10.

Niyazi M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, Geisler J, la Fougere C, Ertl L, Linn J, Siefert A, Belka C (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82(1):67–76. doi:10.1016/j.ijrobp.2010.09.002 CrossRefPubMed

11.

Adkison JB, Tome W, Seo S, Richards GM, Robins HI, Rassmussen K, Welsh JS, Mahler PA, Howard SP (2011) Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys 79(3):835–841. doi:10.1016/j.ijrobp.2009.11.058 CrossRefPubMed

12.

Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neurooncol 103(3):683–691. doi:10.1007/s11060-010-0446-8 CrossRefPubMed

13.

Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C, Evans JJ, Hyslop T, Pequignot E, Downes B, Comber E, Maltenfort M, Dicker AP, Werner-Wasik M (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28(18):3048–3053. doi:10.1200/JCO.2009.25.6941 CrossRefPubMedPubMedCentral

14.

Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156–163. doi:10.1016/j.ijrobp.2008.10.043 CrossRefPubMedPubMedCentral

15.

Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89(2):205–210. doi:10.1007/s11060-008-9607-4 CrossRefPubMed

16.

Grosu AL, Weber WA, Franz M, Stark S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519. doi:10.1016/j.ijrobp.2005.01.056 CrossRefPubMed

17.

Bartsch R, Weitmann HD, Pennwieser W, Wenzel C, Muschitz S, Baldass M, Hassler M, Marosi C, Rossler K, Potter R, Dieckmann K (2005) Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien Klin Wochenschr 117(23–24):821–826. doi:10.1007/s00508-005-0475-z CrossRefPubMed

18.

Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869. doi:10.1200/JCO.2005.03.4157 CrossRefPubMed

19.

Magnuson W, Ian Robins H, Mohindra P, Howard S (2014) Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. J Neurooncol 117(1):133–139. doi:10.1007/s11060-014-1363-z CrossRefPubMed

20.

Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE 2nd, Peters KB, Allen K, Hoang JK, Chang Z, Craciunescu O, Vredenburgh JJ, Friedman HS, Kirkpatrick JP (2013) Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys 86(5):873–879. doi:10.1016/j.ijrobp.2013.04.029 CrossRefPubMed

21.

Cuneo KC, Vredenburgh JJ, Desjardins A, Peters K, Sampson J, Allen K, Chang Z, Duffy E, Peterson B, Kirkpatrick JP (2012) Impact of concurrent and adjuvant Bevacizumab on the risk of radiation necrosis following radiosurgery for recurrent glioma. Int J Radiat Oncol Biol Phys 84(3):S7CrossRef

22.

Torcuator RG, Thind R, Patel M, Mohan YS, Anderson J, Doyle T, Ryu S, Jain R, Schultz L, Rosenblum M, Mikkelsen T (2010) The role of salvage reirradiation for malignant gliomas that progress on bevacizumab. J Neurooncol 97(3):401–407. doi:10.1007/s11060-009-0034-y CrossRefPubMed

23.

Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43(2):293–298CrossRefPubMed

24.

Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J (2013) Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol 52(1):147–152. doi:10.3109/0284186X.2012.692882 CrossRefPubMed

25.

Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45(5):1133–1141CrossRefPubMed

26.

Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, Brada M (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37(2):393–398CrossRefPubMed

27.

Vordermark D, Kolbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55. doi:10.1186/1471-2407-5-55 CrossRefPubMedPubMedCentral

28.

Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26(13):2192–2197. doi:10.1200/JCO.2007.14.8163 CrossRefPubMed

29.

Peca C, Pacelli R, Elefante A, Del Basso De Caro ML, Vergara P, Mariniello G, Giamundo A, Maiuri F (2009) Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg 111 (4):331–334. doi:10.1016/j.clineuro.2008.11.003 CrossRefPubMed

30.

Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM (2014) Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol 16(3):414–420. doi:10.1093/neuonc/not198 CrossRefPubMed

31.

Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin J, Filss C, Langen KJ, Schafer N, Mack F, Schuller H, Simon M, Glas M, Pietsch T, Urbach H, Herrlinger U (2012) Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide. J Clin Oncol 30(21):e180–e183. doi:10.1200/JCO.2011.40.9565 CrossRefPubMed

32.

Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ (2012) Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol 33(3):556–562. doi:10.3174/ajnr.A2811 CrossRefPubMed

33.

Hein PA, Eskey CJ, Dunn JF, Hug EB (2004) Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 25(2):201–209PubMed

34.

Tsien C, Galban CJ, Chenevert TL, Johnson TD, Hamstra DA, Sundgren PC, Junck L, Meyer CR, Rehemtulla A, Lawrence T, Ross BD (2010) Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 28(13):2293–2299. doi:10.1200/JCO.2009.25.3971 CrossRefPubMedPubMedCentral

35.

Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32(11):1978–1985. doi:10.3174/ajnr.A2397 CrossRefPubMed

36.

Tome WA, Howard SP (2007) On the possible increase in local tumour control probability for gliomas exhibiting low dose hyper-radiosensitivity using a pulsed schedule. Br J Radiol 80(949):32–37. doi:10.1259/bjr/15764945 CrossRefPubMed

37.

Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW (1997) Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 20(3):226–229CrossRefPubMed

38.

Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23(2):155–159CrossRefPubMed

39.

Arcicasa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo MG (1999) Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys 43(4):789–793CrossRefPubMed

40.

Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 185(4):235–240. doi:10.1007/s00066-009-1753-x CrossRefPubMed

41.

Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE (2005) Salvage temozolomide for prior temozolomide responders. Cancer 104(11):2473–2476. doi:10.1002/cncr.21564 CrossRefPubMed

42.

Weller M, Tabatabai G, Kastner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bahr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkhah G, Meixensberger J, Vajkoczy P, Kollias S, Husing J, Reifenberger G, Wick W, Group DS (2015) MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the director trial. Clin Cancer Res 21(9):2057–2064. doi:10.1158/1078-0432.CCR-14-2737 CrossRefPubMed

43.

Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12(15):4738–4746. doi:10.1158/1078-0432.CCR-06-0596 CrossRefPubMed

44.

Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Grewal J, Prabhu S, Loghin M, Gilbert MR, Jackson EF (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79(5):1487–1495. doi:10.1016/j.ijrobp.2009.12.061 CrossRefPubMedPubMedCentral

45.

Goglia AG, Delsite R, Luz AN, Shahbazian D, Salem AF, Sundaram RK, Chiaravalli J, Hendrikx PJ, Wilshire JA, Jasin M, Kluger HM, Glickman JF, Powell SN, Bindra RS (2015) Identification of novel radiosensitizers in a high-throughput, cell-based screen for DSB repair inhibitors. Mol Cancer Ther 14(2):326–342. doi:10.1158/1535-7163.MCT-14-0765 CrossRefPubMed

Title: The evolving role for re-irradiation in the management of recurrent grade 4 glioma
Authors: Steven P. Howard
Andra Krauze
Mike D. Chan
Christina Tsien
Wolfgang A. Tomé
Publication date: 01-09-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2392-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The evolving role for re-irradiation in the management of recurrent grade 4 glioma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations

Pediatric high-grade glioma: current molecular landscape and therapeutic approaches

Molecular markers in glioma

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

Immunotherapy and radiation in glioblastoma

State of the art: the evolving role of RT in combined modality therapy for GBM